Raymond James & Associates Humacyte, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Humacyte, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 43,278 shares of HUMA stock, worth $76,169. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,278Holding current value
$76,169% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
169Shares Held
54.4MCall Options Held
1.1MPut Options Held
808K-
Black Rock Inc. New York, NY7.14MShares$12.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$12.3 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$7.73 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT3.43MShares$6.04 Million0.42% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$5.19 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $181M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...